As filed with the Securities and Exchange Commission on March 14, 2018
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Rhythm Pharmaceuticals, Inc.
(Exact name of Registrant as specified in its charter)
Delaware |
| 46-2159271 |
(State or other jurisdiction of |
| (I.R.S. Employer |
500 Boylston Street
11th Floor
Boston, MA 02116
(Address of Principal Executive Offices)
2017 Equity Incentive Plan
(Full Title of the Plan)
Keith M. Gottesdiener, M.D.
Chief Executive Officer and President
Rhythm Pharmaceuticals, Inc.
500 Boylston Street
11th Floor
Boston, MA 02116
(857) 264-4280
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | o | Accelerated filer | o |
|
|
|
|
Non-accelerated filer | x (Do not check if a smaller reporting company) | Smaller reporting company | o |
|
|
|
|
| Emerging growth company | x | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. o
CALCULATION OF REGISTRATION FEE
Title of Each Class of |
| Amount |
| Proposed |
| Proposed |
| Amount of |
| |||
Common Stock, $0.001 par value per share |
|
|
|
|
|
|
|
|
| |||
2017 Equity Incentive Plan |
| 1,091,366 | (2) | $ | 27.12 | (3) | $ | 29,595,106.66 | (3) | $ | 3,684.59 |
|
Total |
| 1,091,366 |
|
|
|
|
| $ | 3,684.59 |
| ||
|
|
|
|
|
|
|
|
|
| |||
(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the Registrant’s common stock that become issuable under the 2017 Equity Incentive Plan (the “EIP”) by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock.
(2) Represents shares of common stock that were automatically added to the shares authorized for issuance under the EIP on January 1, 2018 pursuant to an “evergreen” provision contained in the EIP. Pursuant to such provision, on January 1st of each year commencing in 2018 and continuing through and including January 1, 2027, the number of shares authorized for issuance under the EIP is automatically increased by four percent (4%) of the aggregate number of shares of the Registrant’s capital stock outstanding as of December 31st of the preceding calendar year, or such lesser number of shares that may be determined by the Registrant’s Board of Directors.
(3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to this offering under Rules 457(c) and 457(h) of the Securities Act. The offering price per share and the aggregate offering price for shares reserved for future issuance under the EIP are based on the average of the high and low price per share of the Registrant’s common stock as reported on The Nasdaq Global Market (“Nasdaq”) on March 9, 2018, which is equal to $27.12.
INCORPORATION OF DOCUMENTS BY REFERENCE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,091,366 shares of common stock of Rhythm Pharmaceuticals, Inc. (the “Company”) to be issued pursuant to the Rhythm Pharmaceuticals, Inc. 2017 Equity Incentive Plan. The Company previously registered shares of its Common Stock for issuance under the 2017 Equity Incentive Plan under a Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on October 12, 2017 (File No. 333-220925). Pursuant to General Instruction E to Form S-8, this Registration Statement hereby incorporates by reference the contents of the Registration Statement referenced above.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein.
Exhibit Index
Exhibit |
| Exhibit Description |
| Filed Herewith |
|
|
|
|
|
5.1 |
|
| X | |
|
|
|
|
|
23.1 |
| Consent of Ernst & Young LLP, independent registered public accounting firm. |
| X |
|
|
|
|
|
23.2 |
| Consent of Morgan, Lewis & Bockius LLP. Reference is made to Exhibit 5.1. |
| X |
|
|
|
|
|
24.1 |
| Power of Attorney. Reference is made to the signature page hereto. |
| X |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts on March 14, 2018.
| RHYTHM PHARMACEUTICALS, INC. | |
|
|
|
|
|
|
| By: | /s/ Keith M. Gottesdiener |
|
| Keith M. Gottesdiener |
|
| President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Keith M. Gottesdiener and Hunter Smith and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.
Signature |
| Title |
| Date |
|
|
|
|
|
/s/ Keith M. Gottesdiener |
| Chief Executive Officer, President and Director |
| March 14, 2018 |
Keith M. Gottesdiener |
| (Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Hunter Smith |
| Chief Financial Officer and Treasurer |
| March 14, 2018 |
Hunter Smith |
| (Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
/s/ John J. Hulburt |
| Controller |
| March 14, 2018 |
John J. Hulburt |
|
|
|
|
|
|
|
|
|
/s/ Neil Exter |
| Director |
| March 14, 2018 |
Neil Exter |
|
|
|
|
|
|
|
|
|
/s/ Todd Foley |
| Director |
| March 14, 2018 |
Todd Foley |
|
|
|
|
|
|
|
|
|
/s/ Christophe R. Jean |
| Director |
| March 14, 2018 |
Christophe R. Jean |
|
|
|
|
|
|
|
|
|
/s/ Ed Mathers |
| Director |
| March 14, 2018 |
Ed Mathers |
|
|
|
|
|
|
|
|
|
/s/ David W. J. McGirr |
| Director |
| March 14, 2018 |
David W. J. McGirr |
|
|
|
|
|
|
|
|
|
/s/ David P. Meeker |
| Director |
| March 14, 2018 |
David P. Meeker |
|
|
|
|
